Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO 2014: news, hopes, hypes?

ASCO 2014: news, hopes, hypes? editorial memo (2014) 7:196–197 DOI 10.1007/s12254-014-0189-x Wolfgang Eisterer Received: 6 November 2014 / Accepted: 17 November 2014 / Published online: 28 November 2014 © Springer-Verlag Wien 2014 Wolfgang Eisterer This year’s American Society of Clinical Oncology (ASCO) In the treatment of locally advanced head and neck saw some major improvements in the treatment of tumors concomitant chemoradiotherapy is considered as patients with solid tumors which, however, did not lead standard of care. Owing to the fact that systemic relapse to a change in current clinical practice; at least not in the occurs frequently during follow-up in these patients treatment of those solid tumors which will be reported strategies that include systemic therapy have been devel- within this summary. Surprisingly not all the therapeutic oped. Special interest has focused on the concept of progress stems from targeted therapy but also from long- sequential therapy meaning induction chemotherapy known substances like aromatase inhibitors. In total, before chemoradiotherapy. Numerous phase III stud- more than 5000 abstracts have been presented at ASCO ies have failed to show an improvement in survival for 2014. Within this review the most important abstracts cov- induction chemotherapy [3–5]. An Italian phase III study ering head and neck http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASCO 2014: news, hopes, hypes?

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/asco-2014-news-hopes-hypes-h7CNQiiMfU
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0189-x
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2014) 7:196–197 DOI 10.1007/s12254-014-0189-x Wolfgang Eisterer Received: 6 November 2014 / Accepted: 17 November 2014 / Published online: 28 November 2014 © Springer-Verlag Wien 2014 Wolfgang Eisterer This year’s American Society of Clinical Oncology (ASCO) In the treatment of locally advanced head and neck saw some major improvements in the treatment of tumors concomitant chemoradiotherapy is considered as patients with solid tumors which, however, did not lead standard of care. Owing to the fact that systemic relapse to a change in current clinical practice; at least not in the occurs frequently during follow-up in these patients treatment of those solid tumors which will be reported strategies that include systemic therapy have been devel- within this summary. Surprisingly not all the therapeutic oped. Special interest has focused on the concept of progress stems from targeted therapy but also from long- sequential therapy meaning induction chemotherapy known substances like aromatase inhibitors. In total, before chemoradiotherapy. Numerous phase III stud- more than 5000 abstracts have been presented at ASCO ies have failed to show an improvement in survival for 2014. Within this review the most important abstracts cov- induction chemotherapy [3–5]. An Italian phase III study ering head and neck

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 28, 2014

References

  • Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials
    Pagani, O; Regan, MM; Walley, B
  • First results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer
    Piccart-Gebhart, MJ; Holmes, AP; Baselga, J
  • Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial
    Haddad, R; OʼNeill, AO; Rabinowits, G
  • A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
    Hitt, R; Grau, JJ; Lopez-Pousa, A
  • Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer
    Cohen, EEW; Karrison, TG; Kocherginsky, M
  • Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
    Ghi, MG; Paccagnella, A; Ferrari, D
  • COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
    Long, GV; Stroyakovsky, DL; Gogas, H
  • Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFRmut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 and LUX-Lung 6) comparing afatinib with chemotherapy (CT)
    Yang, JC; Sequist, LV; Schuler, M
  • A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (Pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
    Thatcher, N; Hirsch, FR; Szczesna, A
  • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
    Venook, A; Niedzwiecki, D; Lenz, HJ